<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00533637</url>
  </required_header>
  <id_info>
    <org_study_id>NLA-C004P</org_study_id>
    <nct_id>NCT00533637</nct_id>
  </id_info>
  <brief_title>Taste and Local Tolerance Study of NLA Nasal Spray in Patients With Allergic Rhinitis</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Cross-Over, Allergen Challenge Study to Evaluate Taste and Local Tolerance of NLA Nasal Spray in Patients With Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biolipox AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biolipox AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of NLA Nasal Spray with regard to taste perversion and local tolerance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral or intranasal antihistamines is the first line treatment for allergic rhinitis.&#xD;
      Cetirizine is a second-generation selective antihistamine widely used in an oral formulation&#xD;
      for the treatment of allergic rhinitis. Local administration of cetirizine has been shown to&#xD;
      reduce symptoms after allergen challenge, and has the potential to shorten the time to onset&#xD;
      and decrease systemic side effects. However, local irritation and nasal burning/pain has been&#xD;
      reported after nasal administration. For the compliance of the patients taking a nasal spray,&#xD;
      the taste and tolerance of the product is of particular importance. NLA Nasal Spray contains&#xD;
      cetirizine in a liposomal formulation aiming to improve the tolerability. The present study&#xD;
      aims to compare the NLA Nasal Spray with cetirizine in an aqueous formulation and placebo&#xD;
      with regard to taste perversion and local tolerance. This will be investigated off-season in&#xD;
      patients with seasonal allergic rhinitis after provocation with allergen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Taste perversion scores</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tolerance scores</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy</measure>
    <time_frame>1 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type and incidence of AEs</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NLA Nasal Spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine dihydrochloride (10 mg/ml) liposomal formulation</intervention_name>
    <description>2x110μL in each nostril twice daily for 7 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetirizine dihydrochloride (10 mg/ml) buffer solution</intervention_name>
    <description>2x110μL in each nostril, as a single dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Citrate buffer with preservatives</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 50 years of age (inclusive)&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18 and 28 kg/m2&#xD;
&#xD;
          -  History of pollen-induced seasonal allergic rhinitis for at least two years and&#xD;
             otherwise healthy&#xD;
&#xD;
          -  Elevated specific IgE to at least one aero allergen or at least one positive skin pick&#xD;
             test (SPT)&#xD;
&#xD;
          -  Seasonal allergic rhinitis with symptoms provoked by the allergen with a corresponding&#xD;
             elevated specific IgE or positive SPT&#xD;
&#xD;
          -  Signed written Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Perennial allergic rhinitis except for cat and/or dog sensitivity under the condition&#xD;
             that these patients are not exposed to cats and dogs&#xD;
&#xD;
          -  Soy bean allergy&#xD;
&#xD;
          -  Peanut allergy&#xD;
&#xD;
          -  Smoking during the last month before study inclusion&#xD;
&#xD;
          -  Any upper respiratory tract infection during the period of 2 weeks before the start of&#xD;
             the study&#xD;
&#xD;
          -  Chronic medication&#xD;
&#xD;
          -  Any medication, including herbal medicines, during their last five half-lives (t½)&#xD;
&#xD;
          -  Nasal anatomical deviations&#xD;
&#xD;
          -  Extensive use of nasal sprays as judged by the Investigator&#xD;
&#xD;
          -  Ongoing nasal symptoms as judged by the Investigator&#xD;
&#xD;
          -  Known hypersensitivity to cetirizine&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Fertile women not using reliable methods of contraception (i.e. IUD, barrier method,&#xD;
             hormonal contraceptives, abstinence)&#xD;
&#xD;
          -  Participation in any other investigational study in the last three months&#xD;
&#xD;
          -  Inability to adhere to the study plan&#xD;
&#xD;
          -  Previous inclusion in this study&#xD;
&#xD;
          -  Blood donation during the last three months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lennart Greiff, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Lund</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Otorhinolaryngology, Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2007</study_first_posted>
  <last_update_submitted>February 29, 2008</last_update_submitted>
  <last_update_submitted_qc>February 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2008</last_update_posted>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Nasal spray</keyword>
  <keyword>Anti-histamine</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

